2016 was a lousy year for biotech investors but TheStreet.com's Adam Feuerstein's biotech tweets were on point! It started when his beloved dog died right after New Year's Day and then MannKind (MNKD) - Get Report went KABOOM! Another bad omen for 2016: A news-free start to the J.P. Morgan Healthcare conference, followed fast by the FDA's decision to postpone the Sarepta (SRPT) - Get Report advisory panel. The year started bad and never really stopped being bad. Let's hope 2017 is better than 2016 and the tweets keep coming @AdamFeuerstein
This article was written by a staff member of TheStreet.